Gentium announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem-cell transplantation (HSCT).
MarketWatch